Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

Biochemical and Biophysical Research Communications

Volumn 407, Issue 1, 2011, Pages 219-224

  Azuma, Koichi ^a   Tsurutani, Junji ^a   Sakai, Kazuko ^a   Kaneda, Hiroyasu ^a   Fujisaka, Yasuhito ^a   Takeda, Masayuki ^a   Watatani, Masahiro ^a   Arao, Tokuzo ^a   Satoh, Taroh ^a   Okamoto, Isamu ^a   Kurata, Takayasu ^a   Nishio, Kazuto ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; CGH; Drug resistance; EGFR; Erk; FGFR2; HER2; IC50; Lapatinib; RNAi; SiRNA; TKI

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; LAPATINIB;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA HYBRIDIZATION; DRUG TARGETING; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SALVAGE THERAPY; TREATMENT FAILURE; TUMOR CELL;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 79953162369     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.002     Document Type: Article

References (14)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008, GLOBOCAN 2008. Int. Cancer. 2010, 127:2893-2917.
2. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987, 235:177-182.
3. DiGiovanna M.P., Stern D.F., Edgerton S.M., et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J. Clin. Oncol. 2005, 20:1152-1160.
4. Konecny G.E., Pegram M.D., Venkatesan N., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66:1630-1639.
5. Scaltriti M., Rojo F., Ocana A., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 2007, 99:628-638.
6. Faratian D., Goltsov A., Lebedeva G., et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009, 69:6713-6720.
7. Eichhorn P.J.A., Gili M., Scaltriti M., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008, 68:9221-9230.
8. Liu L., Greger J., Shi H., et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009, 69:6871-6878.
9. Turner N., Grose R. Fibroblast growth factor signaling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
10. Stacey S.N., Manolescu A., Sulem P., et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 2008, 40:703-706.
11. Dutt A., Salvesen H.B., Chen T.H., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 2008, 105:8713-8717.
12. Ornitz D.M., Marie P.J. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002, 16:1446-1465.
13. Kunii K., Gorenstein D.J., Hatch H., et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008, 68:2340-2348.
14. Mittendorf E.A., Wu Y., Scaltriti M., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin. Cancer Res. 2009, 15:7381-7388.